TY - JOUR
T1 - Recent Advances in the Development of Antibody-Drug Conjugates in Urothelial Cancer
AU - Alhalabi, Omar
AU - Altameemi, Lina
AU - Campbell, Matthew T.
AU - Meric-Bernstam, Funda
N1 - Funding Information:
O.A. is a recipient of the Young Investigator and Career Development Awards from the Conquer Cancer Foundation of the American Society of Clinical Oncology. The authors thank Sarah E. Townsend for the editorial revision of the manuscript.
Publisher Copyright:
© Wolters Kluwer Health, Inc. All rights reserved.
PY - 2022/11/1
Y1 - 2022/11/1
N2 - Antibody-drug conjugates (ADCs) have joined the armamentarium against urothelial cancer (UC) as an effective therapy option. Since 2019, the US Food and Drug Administration has approved 2 ADCs for advanced previously treated UC: enfortumab vedotin, which targets nectin-4 and sacituzumab govitecan, which targets trophoblast cell-surface antigen 2. These ADCs are now being tested in earlier disease settings and in previously untreated patients. Furthermore, novel ADCs (e.g., anti-HER-2) are being tested in the clinic and show promising clinical benefit. The next frontier is to understand the mechanisms of resistance and response, gaining experience with ADC-related adverse events and learning the best strategy to sequence and combine these agents with existing therapies. Here, we highlight the recent advances in the development of ADCs for treating localized and metastatic UC.
AB - Antibody-drug conjugates (ADCs) have joined the armamentarium against urothelial cancer (UC) as an effective therapy option. Since 2019, the US Food and Drug Administration has approved 2 ADCs for advanced previously treated UC: enfortumab vedotin, which targets nectin-4 and sacituzumab govitecan, which targets trophoblast cell-surface antigen 2. These ADCs are now being tested in earlier disease settings and in previously untreated patients. Furthermore, novel ADCs (e.g., anti-HER-2) are being tested in the clinic and show promising clinical benefit. The next frontier is to understand the mechanisms of resistance and response, gaining experience with ADC-related adverse events and learning the best strategy to sequence and combine these agents with existing therapies. Here, we highlight the recent advances in the development of ADCs for treating localized and metastatic UC.
KW - Antibody-drug conjugates
KW - HER-2
KW - nectin-4
KW - Trop-2
KW - tumor-associated antigens
KW - urothelial carcinoma
UR - http://www.scopus.com/inward/record.url?scp=85142402257&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85142402257&partnerID=8YFLogxK
U2 - 10.1097/PPO.0000000000000632
DO - 10.1097/PPO.0000000000000632
M3 - Review article
C2 - 36383903
AN - SCOPUS:85142402257
SN - 1528-9117
VL - 28
SP - 417
EP - 422
JO - Cancer Journal (United States)
JF - Cancer Journal (United States)
IS - 6
ER -